ClinicalTrials.gg
CompletedNCT03745716Updated Mar 18, 2025Results posted

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

A Phase 3 interventional study of APR-246 + azacitidine and Azacitidine in MDS, sponsored by Aprea Therapeutics. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Aprea Therapeutics · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.

Read the detailed description

A Phase III, multicenter, randomized study to compare the rate of CR and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.

Treatment will be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's disease.

Patients will be randomized (1:1) to one of two arms:

  1. Experimental arm: APR-246 + azacitidine; or
  2. Control arm: Azacitidine
02

Conditions studied

  • MDS
03

In context

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed (ICF) and is able to comply with protocol requirements
  • Documented diagnosis of MDS, according to World Health Organization (WHO) classification
  • Patient has adequate organ function as defined by the following laboratory values:

    1. > 30 mL/min (by Cockcroft-Gault method)
    2. Total serum \< 1.5 x (ULN) or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome or hemolysis or who required regular blood transfusions
    3. (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN
  • Age ≥18 years at the time of signing the informed consent form (ICF)
  • Having at least one TP53 mutation which is not benign or likely benign
  • (ECOG) performance status score of 0, 1, or 2
  • If of , negative pre-treatment urine or serum pregnancy test
  • If of childbearing potential (males and females), willing to use an effective form of such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter

Exclusion criteria

Exclusion Criteria:

  • Patient has a known history of (HIV) or active or active infection (testing not mandatory)
  • Patient has any of the following cardiac abnormalities (as determined by treating MD):

    1. Myocardial infarct within six months prior to registration,
    2. Class II or worse heart failure (Appendix II) or known (LVEF) \< the institution lower limit of normal as assessed by echocardiogram
    3. A history of familial long syndrome,
    4. pericardial disease
    5. Electrocardiographic evidence of acute ischemia
    6. Symptomatic atrial or ventricular arrhythmias not controlled by medications
    7. QTc ≥ 470 msec (QT cardiac interval)
    8. Bradycardia (\<40 bpm)
  • Concomitant or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis
  • Prior exposure to azacitidine, decitabine or hypomethylating agent
  • Prior exposure to intensive chemotherapy
  • Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment
  • No concurrent use of erythroid stimulating agents
  • Patients with history of stem cell transplantation
  • Pregnant women are excluded from this study because APR-246 has not been studied in pregnant patients. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR 246, breastfeeding should be discontinued if the mother is treated with APR-246.
  • Patients with active uncontrolled infections
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Experimental arm: APR-246 + azacitidine

    Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):

    Drug: APR-246 + azacitidine

  • Experimental
    Control arm: Azacitidine

    Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):

    Drug: Azacitidine

Interventions

  • DrugAPR-246 + azacitidine

    Drug pages: EprenetapoptStudies of EprenetapoptEprenetapopt pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65): Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine

  • Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65): Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CR)

    To compare the complete response rate, defined as the proportion of patients who achieve complete remission (CR) with APR 246 + azacitidine treatment vs. azacitidine only.

    Time frame: 12 months

07

Results

Posted Jul 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneExperimental Arm: APR-246 + AzacitidineControl Arm: Azacitidine
Started7876
Completed7574
Not completed32

Outcome measures

PrimaryComplete Response Rate (CR)

To compare the complete response rate, defined as the proportion of patients who achieve complete remission (CR) with APR 246 + azacitidine treatment vs. azacitidine only.

Time frame:
12 months
Reported as:
Count of participants · Participants
Complete Response Rate (CR)
ParticipantsExperimental Arm: APR-246 + AzacitidineControl Arm: Azacitidine
Complete Response Rate (CR)2717

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm: APR-246 + Azacitidine46/78 (59%)53/76 (69.7%)76/76 (100%)
Control Arm: Azacitidine36/76 (47.4%)38/61 (62.3%)61/61 (100%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventExperimental Arm: APR-246 + AzacitidineControl Arm: Azacitidine
Febrile neutropeniaBlood and lymphatic system disorders25/7614/61
PneumoniaInfections and infestations8/768/61
PyrexiaGeneral disorders6/764/61
SepsisInfections and infestations5/764/61
Muscular weaknessMusculoskeletal and connective tissue disorders5/762/61
Respiratory failureRespiratory, thoracic and mediastinal disorders4/761/61
Confusional statePsychiatric disorders3/763/61
Septic shockInfections and infestations3/761/61
AnemiaBlood and lymphatic system disorders0/762/61
ThrombocytopeniaBlood and lymphatic system disorders0/762/61
Most frequent other events
Showing 10 of 43
Most frequent other events
EventExperimental Arm: APR-246 + AzacitidineControl Arm: Azacitidine
NauseaGastrointestinal disorders51/7621/61
ConstipationGastrointestinal disorders48/7632/61
VomitingGastrointestinal disorders40/768/61
White blood cell count decreasedInvestigations31/7629/61
Neutrophil count decreasedInvestigations34/7623/61
AnemiaBlood and lymphatic system disorders33/7627/61
Platelet count decreasedInvestigations25/7626/61
Febrile neutropeniaBlood and lymphatic system disorders31/7616/61
FatigueGeneral disorders30/7620/61
HeadacheNervous system disorders24/7613/61

Baseline characteristics

ITT

Age, Categorical
Age, Categorical(Participants)Experimental Arm: APR-246 + AzacitidineControl Arm: AzacitidineTotal
<=18 years000
Between 18 and 65 years222244
>=65 years5654110
Age, Continuous
Age, Continuous(years)Experimental Arm: APR-246 + AzacitidineControl Arm: AzacitidineTotal
Median69 (34 to 90)69.5 (29 to 86)69 (29 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm: APR-246 + AzacitidineControl Arm: AzacitidineTotal
Female362965
Male424789
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental Arm: APR-246 + AzacitidineControl Arm: AzacitidineTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American145
White6158119
More than one race000
Unknown or Not Reported151227
Region of Enrollment
Region of Enrollment(participants)Experimental Arm: APR-246 + AzacitidineControl Arm: AzacitidineTotal
United States6567132
France13922
08

Study locations

27 sites
  • City of Hope
    Duarte, California 91010, United States
  • Stanford University Cancer Research Center
    Palo Alto, California 94304, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Memorial Health Care System South Florida
    Hollywood, Florida 33021, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Moffitt Cancer Center
    Tampa, Florida 12902, United States
  • Robert H Lurie Comprehensive Cancer Center, Northwestern University
    Chicago, Illinois 60611, United States
  • University Of Chicago Medicine
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinics, Holden Cancer Center
    Iowa City, Iowa 52242, United States
  • Ochsner Cancer Institute
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins Medical Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Washington University St. Louis
    Saint Louis, Missouri 63130, United States
  • Cornell Medical Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center, Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 19023, United States
  • CHU Nantes
    Nantes, 44093, France
  • CHU Nice
    Nice, 06000, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • IUCT Oncopole
    Toulouse, 31100, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Nov 2020, 22 months.

Results were first posted in Jul 2022, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2018
First posted
Nov 19, 2018
StartActual
Jan 11, 2019
Primary completionActual
Nov 27, 2020
CompletionActual
Jan 14, 2022
Results first posted
Jul 12, 2022
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03745716
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Jan 11, 2019
Primary completion
Nov 27, 2020
Completion
Jan 14, 2022
Results posted
Jul 12, 2022
Last update
Mar 18, 2025

Study contacts

David Sallman, MD, PhD
principal investigator · Moffitt Cancer Center, Tampa, US

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eprenetapopt · Azacitidine

Start the discussion